-
1 Comment
Cara Therapeutics, Inc is currently in a long term downtrend where the price is trading 15.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.7.
Cara Therapeutics, Inc's total revenue rose by 2384.8% to $112M since the same quarter in the previous year.
Its net income has increased by 375.8% to $79M since the same quarter in the previous year.
Finally, its free cash flow grew by 362.9% to $82M since the same quarter in the previous year.
Based on the above factors, Cara Therapeutics, Inc gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US1407553072 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | nan |
|---|---|
| Market Cap | None |
| PE Ratio | nan |
| Target Price | nan |
| Dividend Yield | nan% |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 69C.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
